2,2,2-trifluoroethyl trifluoromethane sulfonate | 357333-09-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: 2,2,2-trifluoroethyl trifluoromethane sulfonate
• 英文别名: 1,1,1-trifluoro-2-((trifluoromethyl)sulfonyl)ethane；2,2,2-trifluoroethyltriflate；1,1,1-Trifluoro-2-(trifluoromethylsulfonyl)ethane
• CAS: 357333-09-6
• 化学式: C₃H₂F₆O₂S
• 分子量: 216.104
• InChiKey: VPZPABOPLZNFGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2,2,2-trifluoroethyl trifluoromethane sulfonate 、 tert-butyl 2-methyl-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxylate 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以94%的产率得到tert-butyl 2-methyl-1-(2,2,2-trifluoroethyl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxylate
  参考文献：
  名称：

  TW2017/8220

  摘要：

  公开号：

文献信息

• [EN] COMPLEMENT PATHWAY MODULATORS AND USES THEREOF<br/>[FR] MODULATEUR DE LA VOIE D'ACTIVATION DU COMPLÉMENT ET SES UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2013192345A1

  公开（公告）日：2013-12-27

  The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物I的方法，用于制造该发明的化合物，并且作为抑制补体替代途径的治疗用途，特别是作为抑制因子B的治疗用途，例如用于治疗年龄相关性黄斑变性和糖尿病视网膜病变。本发明还提供了一种药理活性剂的组合和一种制药组合物。
• Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals
  申请人：Keil Stefanie

  公开号：US20080261979A1

  公开（公告）日：2008-10-23

  The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator receptor (PPARdelta) agonist activity. The compounds of the present invention are comprised of the formula: wherein the substituents R1-R5 and R7-R10 are defined herein. The compounds are therapeutically effective in the regulation and modulation of lipid and carbohydrate metabolism in mammals and are thus suitable for the treatment of diseases such as type-2 diabetes, atherosclerosis, cardiovascular disorders and the like.

  本发明的创新化合物由苯基和吡啶基-1,2,4-噁二唑酮衍生物以及它们的生理上可接受的盐和功能衍生物组成，已被证明具有过氧化物酶体增殖激活受体（PPARδ）激动剂活性。本发明的化合物由以下公式组成：其中取代基R1-R5和R7-R10在此定义。这些化合物在哺乳动物的脂质和碳水化合物代谢的调节和调控方面具有治疗效果，因此适用于治疗糖尿病、动脉粥样硬化、心血管疾病等疾病。
• Remote Electronic Control in the Regioselective Reduction of Succinimides: A Practical, Scalable Synthesis of EP4 Antagonist MF-310
  作者：Carmela Molinaro、Danny Gauvreau、Gregory Hughes、Stephen Lau、Sophie Lauzon、Rémy Angelaud、Paul D. O’Shea、Jacob Janey、Michael Palucki、Scott R. Hoerrner、Conrad E. Raab、Rick R. Sidler、Michel Belley、Yongxin Han

  DOI：10.1021/jo901267x

  日期：2009.9.4

  A practical large-scale chromatography-free synthesis of EP4 antagonist MF-310, a potential new treatment for chronic inflammation, is presented. The synthetic route provided MF-310 as its sodium salt in 10 steps and 17% overall yield from commercially available pyridine dicarboxylate 7. The key features of this sequence include a unique regioselective reduction of succinimide 2 controlled by the electronic-properties of a remote pyridine ring, preparation of cyclopropane carboxylic acid 3 via a Corey-Chaykovsky cyclopropanation, and a short synthesis of sulfonamide 5.
• 10.1016/j.bmcl.2024.129854
  作者：Takano, Ryota、Tanaka, Ryoko、Nakamura, Kayo、Tabata, Hidetsugu、Oshitari, Tetsuta、Natsugari, Hideaki、Takahashi, Hideyo

  DOI：10.1016/j.bmcl.2024.129854

  日期：——
• TW2017/8220
  申请人：——

  公开号：——

  公开（公告）日：——